Skip to main content

6 Result(s)

within Sabrina Rossetti Remove this filter

and

  1. Article

    Open Access

    Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

    Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone...

    Pier Vitale Nuzzo, Filippo Pederzoli, Calogero Saieva… in Journal of Translational Medicine (2023)

    Download PDF (792 KB) View Article

  2. Article

    Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

    While typesetting the article the Table 3 column/row entries are interchanged. Please find below the updated Table

    Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, Michele Milella… in Targeted Oncology (2020)

    Download PDF (350 KB) View Article

  3. No Access

    Article

    Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223

    To evaluate the fracture risk and survival outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) who received sequentially abiraterone acetate (AA) and radium 223 [223Ra]RaCl2 in the d...

    Orazio Caffo, Viviana Frantellizzi… in European Journal of Nuclear Medicine and M… (2020)

  4. No Access

    Article

    Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis

    Angiogenesis has been recognized as the most important factor for tumor invasion, proliferation, and progression in metastatic renal cell carcinoma (mRCC). However, few clinical data are available regarding th...

    Roberto Iacovelli, Chiara Ciccarese, Gaetano Facchini, Michele Milella… in Targeted Oncology (2020)

  5. Article

    Open Access

    Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

    This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients.

    Gaetano Facchini, Sabrina Rossetti… in Journal of Translational Medicine (2019)

    Download PDF (1107 KB) View Article

  6. Article

    Open Access

    Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

    The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.

    Elena Verzoni, Giacomo Cartenì, Enrico Cortesi… in Journal for ImmunoTherapy of Cancer (2019)

    Download PDF (748 KB) View Article